ChemDiv Continues R&D Services for Clywedog Following Merger with Barinthus Therapeutics

ChemDiv will continue providing chemistry, computational, and clinical pharmacology support to Clywedog Therapeutics following its merger with Barinthus Therapeutics. The combined entity will operate under the name Clywedog Therapeutics and focus on advancing clinical-stage candidates in Type 1 diabetes, Type 2 diabetes, and celiac disease. ChemDiv's services were instrumental in differentiating MEN PPI inhibitors and TYK2 inhibitors for Clywedog's programs, which progressed from discovery to clinic in less than three years.